Enhanced Treatment System for Uterine Fibroids using Optimized Collagenase Compositions and Delivery Methods

The present inventive concept relates to a novel system for treating uterine fibroids, featuring optimized collagenase compositions, targeted delivery methods, and real-time monitoring capabilities, providing improved efficacy, safety, and patient outcomes.

The original patent disclosed a method for treating uterine fibroids using purified collagenase. However, the existing method has limitations, including the risk of systemic absorption, inadequate localized tissue breakdown, and the need for improved delivery systems. The present inventive concept addresses these limitations by introducing advanced collagenase compositions, micro-needle array delivery, pH-optimized formulations, and real-time monitoring capabilities.

The new system comprises a collagenase composition having a concentration of 0.25-2.0 mg/mL, which is administered via a micro-needle array for targeted delivery to the fibroid tissue. The composition is formulated to minimize systemic absorption and maximize localized tissue breakdown, with a pH range of 6.5-7.5. Additionally, the system incorporates a collagenase-coated balloon catheter, which is expandable to compress the fibroid tissue and facilitate collagenase delivery. The composition may further include a proteoglycan-degrading enzyme, which synergistically breaks down fibroid tissue and promotes tissue remodeling. The system also features a fibroid tissue stiffness sensor, providing real-time feedback on treatment efficacy.

The new claims introduce several novel and non-obvious features, including the use of micro-needle arrays, pH-optimized formulations, collagenase-coated balloon catheters, and proteoglycan-degrading enzymes. These advancements provide improved efficacy, safety, and patient outcomes, distinguishing the present inventive concept from the original patent.

Alternative embodiments of the inventive concept may include varying the collagenase composition concentration, using different delivery methods such as jet injectors or syringes, or incorporating additional enzymes or bioactive molecules to enhance tissue breakdown and remodeling. Other variations may involve modifying the balloon catheter design or incorporating imaging modalities to enhance treatment monitoring.

The enhanced treatment system for uterine fibroids has significant commercial potential in the medical device and pharmaceutical industries, offering a novel solution for a common and debilitating condition affecting millions of women worldwide. The market potential includes hospitals, clinics, and medical centers, as well as potential partnerships with pharmaceutical companies and medical device manufacturers.